52085-98-0

Basic information

• Product Name: 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL
• Synonyms: 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL;1H-Inden-1-ol, 6-chloro-2,3-dihydro-;6-Chloro-1-indanol
• CAS NO: 52085-98-0
• Molecular Formula: C₉H₉ClO
• Molecular Weight: 168.62
• Mol File: 52085-98-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 277.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.322±0.06 g/cm3(Predicted)
• PKA: 13.96±0.20(Predicted)
• CAS DataBase Reference: 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL(52085-98-0)
• EPA Substance Registry System: 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL(52085-98-0)

Safety Data

• Hazardous Substances Data: 52085-98-0(Hazardous Substances Data)

Usage

General Description

6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL is a chemical compound that belongs to the class of indene compounds. It is a chlorinated derivative of 2,3-dihydro-1H-inden-1-ol and is characterized by the presence of a chlorine atom at the sixth position of the indene ring. 6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL is utilized in the synthesis of various pharmaceutical and agrochemical products due to its unique molecular structure and reactivity. Its chemical properties make it suitable for the production of a wide range of organic compounds and it is commonly used as a building block in the chemical industry for the development of novel substances with valuable applications in different fields.

Upstream product

• 14548-38-0 6-chloro-1-indanone 

Downstream Products

• 3970-51-2 5-chloro-1H-indene 
• 872182-08-6 (R)-6-chloro-2,3-dihydro-1H-inden-1-ol 
• 872182-06-4 (S)-6-chloro-2,3-dihydro-1H-inden-1-ol 
• 14548-38-0 6-chloro-1-indanone 
• 1427414-93-4 (1aS,6aR)-3-chloro-6,6a-dihydro-1aH-1-oxa-cyclopropa[a]-indene 
• 1119270-39-1 2-(5-chloro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-1-{1-[(2E)-3-(3,5-difluorophenyl)-2-propenoyl]-4-piperidinyl}ethanol 
• 872181-01-6 2-(6-chloroindan-1-yloxy)-6-fluorobenzonitrile 
• 34784-06-0 7-chloroisoquinoline 

Relevant articles and documents

Kinetic resolution of racemic benzofused alcohols catalysed by HMFO variants in presence of natural deep eutectic solvents

5-Hydroxymethylfurfural oxidase (HMFO) has demonstrated to be a useful biocatalyst for the selective oxidation of alcohols employing oxygen as mild oxidant with no requirement of expensive organic cofactors. This wild-type HMFO biocatalyst and an engineered thermostable variant have been tested in the kinetic resolution of different benzofused alcohols. The use of natural deep eutectic solvents was also explored in HMFO-catalysed oxidation of alcohols. The oxidation of racemic 1-indanol showed a higher conversion and selectivity in presence of 60% v/v of different NADES, especially for those containing carbohydrates. By choosing properly the biocatalyst and the NADES, good enantioselectivity values can be obtained, demonstrating the advantages of employing these neoteric solvents in biocatalysed processes.

Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na+/H+ Exchanger Type 3 (NHE3)

The design, synthesis, and structure-activity relationship of 1-phenoxy-2-aminoindanes as inhibitors of the Na+/H+ exchanger type 3 (NHE3) are described based on a hit from high-throughput screening (HTS). The chemical optimization resulted in the discovery of potent, selective, and orally bioavailable NHE3 inhibitors with 13d as best compound, showing high in vitro permeability and lacking CYP2D6 inhibition as main optimization parameters. Aligning 1-phenoxy-2-aminoindanes onto the X-ray structure of 13d then provided 3D-QSAR models for NHE3 inhibition capturing guidelines for optimization. These models showed good correlation coefficients and allowed for activity estimation. In silico ADMET models for Caco-2 permeability and CYP2D6 inhibition were also successfully applied for this series. Moreover, docking into the CYP2D6 X-ray structure provided a reliable alignment for 3D-QSAR models. Finally 13d, renamed as SAR197, was characterized in vitro and by in vivo pharmacokinetic (PK) and pharmacological studies to unveil its potential for reduction of obstructive sleep apneas.

SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof; where R1-R5, Y, m, n, and p are defined herein. Compounds and compositions of the present invention are useful the treatment of atherosclerosis.